 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|||||||||||||
|
[ back to News ] Concert Pharmaceuticals to Participate in Drug Discovery and Development Panel at 2010 BIO International Convention
|
|||||||||||||||
Lexington, MA –– Concert Pharmaceuticals, Inc. announced today that the company will be participating at the 2010 BIO International Convention being held at McCormick Place in Chicago, IL, May 3-6, 2010. Roger Tung, Ph.D., Concert’s President and Chief Executive Officer, will be presenting on a Drug Discovery and Development panel entitled, “Challenging the Conventional Wisdom – Re-emergence of Innovative Chemistry for Breakthrough Drugs,” at 4:00 P.M. CDT on Wednesday, May 5, 2010.
About Concert
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE (deuterated chemical entity) platform to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc.
[ back to top ]
|
|
|
|
|
| ©2009 Concert Pharmaceuticals, Inc. Design by Digizyme |
||||
|
|
|
|
|